MedTrace Logo

HKI-272 Ketoconazole Drug Interaction Study

NCT00380328 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2012-05-14

No results posted yet for this study

Summary

To investigate a potential pharmacokinetic drug interaction between HKI-272 and ketoconazole when co-administered.

Conditions

  • Healthy

Interventions

DRUG

neratinib

HKI-272

Sponsors & Collaborators

  • Puma Biotechnology, Inc.

    lead INDUSTRY

Principal Investigators

  • Puma · Biotechnology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-10-31
Completion
2006-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00380328 on ClinicalTrials.gov